Every lot published · search any lot number before you order

Retatrutide vs Tirzepatide: Which Has the Stronger Weight-Loss Evidence?

Retatrutide showed substantial weight reductions in placebo-controlled obesity trials. Tirzepatide has its own randomized obesity studies, including SURMOUNT-1, with different populations and time points.

Retatrutide vs Tirzepatide: Which Has the Stronger Weight-Loss Evidence?. The direct trial is TRIUMPH-5. Retatrutide, TRIUMPH-5, Tirzepatide. GLP LIFE SCIENCES ยท RESEARCH BRIEF 31 The direct trial is TRIUMPH-5 Comparisons RetatrutideTRIUMPH-5Tirzepatide
The direct trial is TRIUMPH-5. Illustration for this research brief.

The direct trial is TRIUMPH-5

TRIUMPH-5 directly compares retatrutide with tirzepatide in adults with obesity. As of November 6, 2026, a head-to-head result was not found in the cited study record or sponsor materials.

InterventionTrialFollow-upMean weight reductionContext
RetatrutideTRIUMPH-180 weeks28.3% vs 2.2% placeboSponsor efficacy analysis; 12 mg arm
TirzepatideSURMOUNT-172 weeks20.9% vs 3.1% placebo15 mg arm
SemaglutideSTEP 168 weeks14.9% vs 2.4% placebo2.4 mg arm
Separate placebo-controlled trials with different protocols.

These percentages come from separate trials. Their populations, study durations, analysis methods and placebo responses differ. In SURMOUNT-5, the direct tirzepatide and semaglutide comparison yielded 20.2% and 13.7% mean reductions, respectively, at 72 weeks.

How to interpret the evidence

The evidence establishes placebo-controlled effects for both molecules. A claim about which causes greater weight loss in a common population depends on the direct comparison.

Give the strongest weight to studies that randomized both treatments within a shared protocol for the clinical question you are asking.

Sources